QUOIN PHARMACEUTICALS LT-ADR (QNRX)

US74907L3006 - ADR

0.6  +0.04 (+7.14%)

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (12/19/2024, 1:13:42 PM)

0.6

+0.04 (+7.14%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%75.9%
Sales Q2Q%N/A
CRS7.23
6 Month-8.15%
Overview
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Ins Owners482.24%
Inst Owners4.15%
Market Cap2.39M
Shares3.98M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80
Short Float %1.93%
Short Ratio0.03
IPO11-01 1989-11-01
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

QNRX Daily chart

Company Profile

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Company Info

QUOIN PHARMACEUTICALS LT-ADR

23 Hata'as Street

Kfar Saba

P: 97299741444

CEO: Shai Yarkoni

Employees: 4

Website: https://quoinpharma.com/

QNRX News

ChartMill News Image5 hours ago - ChartmillDiscover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Wondering what's happening in Thursday's pre-market session? Find an overview in this article.

News Image5 hours ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily...

News Imagea day ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin...

ChartMill News Image8 days ago - ChartmillThese stocks are moving in today's after hours session

Top movers in Wednesday's after hours session

ChartMill News Image16 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

News Imagea month ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant...

QNRX Twits

Here you can normally see the latest stock twits on QNRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example